Excavation works carried out by national and foreign archeological teams in the central Syrian Governorate of Hama has yielded several important findings in Tal al-Homsi, Apamea, al-Rawda, Ba'arin Cemetery, Tal al-Qarqour.

The teams also executed many restoration works in the ancient Shaizar Castle.

Head of Hama Department of Ruins Jamal Ramadan said significant parts of Apamea ancient city were unearthed, particularly in the northeastern corners, as well as discovering some findings including a stone statue with intact face.

Mr. Ramadan added that the Syrian-German crew discovered a stone statue of a lioness which was the Symbol of Mamlouki state.

Texas Children’s Hospital has been named the national lead center for a 12-hospital, 36-month clinical trial of the German-manufactured pediatric heart pump called Berlin Heart EXCOR® Pediatric Ventricular Assist Device (VAD).

Charles D. Fraser, Jr., MD, chief of pediatric and congenital heart surgery at Texas Children’s and professor, Michael E. DeBakey Department of Surgery at Baylor College of Medicine, will serve as the National Principal Investigator for the Investigational Device Exemption prospective study.

As levels of carbon dioxide in the atmosphere rise in the 21st century, the nutritional value of many major food crops could decrease, according to a study conducted at Southwestern University.

Max Taub, an associate professor of biology at Southwestern, did a "meta-analysis" of previous research that had been done on the effect of increased atmospheric carbon dioxide on the protein concentrations in barley, rice, wheat, soybean and potato.

His study found that the crops had significantly lower protein concentrations when grown in atmospheres containing elevated levels of carbon dioxide. Potatoes showed a nearly 14 percent decrease in protein, while the grain crops of barley, rice and wheat showed reductions of 15.3 percent, 9.9 percent and 9.8 percent respectively.

Why is it difficult to pick out even a familiar face in a crowd? We all experience this, but the phenomenon has been poorly understood until now.

The results of a recent study may have implications for individuals with face-recognition disorders and visual-attention related ailments — and eventually could help scientists develop an artificial visual system that approaches the sophistication of human visual perception.

The study is part of a recently completed Journal of Vision special issue titled “Crowding: Including illusory conjunctions, surround suppression, and attention”. “Crowding” is a failure to recognize an individual object in a cluttered environment.

New research by Professor Michael Benton and our own Sarda Sahney at the University of Bristol indicate in a Proceedings of the Royal Society B paper that specialized animals forming complex ecosystems, with high biodiversity, complex food webs and a variety of niches, took over 30 million years to recover from the last major extinction.

About 250 million years ago, at the end of the Permian period, a major extinction event killed over 90 per cent of life on earth, including insects, plants, marine animals, amphibians, and reptiles. Ecosystems were destroyed worldwide, communities were restructured and organisms were left struggling to recover.

BARCELONA, Spain, January 18 /PRNewswire/ --

- Centre seeks solutions to challenges and opportunities coming with multi-core processors.

CAMBRIDGE, England and LILLE, France, January 18 /PRNewswire/ --

- Irish and UK Blood Services Continue Pre-Adoption Clinical Evaluation of Filter

- Recent Case of vCJD Now Means That All the Population is Susceptible to the Disease

- Increased Concerns Over "Second Wave" of vCJD in Individuals With Much Longer Incubation Times

- P-Capt(R) Prion Reduction Filter Still the Only Proven Method of Protecting Against Potential Transmission of the Disease in Blood

- ProMetic and MacoPharma Gearing up for Implementation in Watershed Year for the Product

LEUVEN, Belgium and LUND, Sweden, January 18 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International AB (Nordic Exchange: BINV) announce today that they have received approval from the regulatory authorities in Denmark to initiate a Phase I clinical trial of the novel anti-cancer agent TB-403. TB-403 is a monoclonal antibody that targets the angiogenic factor PlGF (placental growth factor). TB-403 has demonstrated strong inhibition of PlGF-associated angiogenesis and tumour growth in animal models, without affecting healthy tissues. This product candidate is being developed within the framework of the alliance between ThromboGenics and BioInvent.